According to our (Global Info Research) latest study, the global Medical Device Testing and Validation Service market size was valued at US$ 10804 million in 2025 and is forecast to a readjusted size of US$ 18999 million by 2032 with a CAGR of 8.4% during review period.
Medical Device Testing and Validation Service refers to outsourced laboratory, engineering and technical verification services used by medical device manufacturers and developers to demonstrate that a device, its materials, components, packaging, software-supported functions and manufacturing-related characteristics meet defined safety, performance, quality and regulatory requirements. The market primarily captures service revenue generated from biological and chemical testing, microbiology and sterility assessment, packaging validation, electrical safety and performance testing, and other specialized verification and validation activities conducted during product development, regulatory submission, design transfer, commercial release and lifecycle management. Testing programs may involve biocompatibility evaluation, chemical characterization, extractables and leachables assessment, microbiological testing, sterilization validation, package integrity and shelf-life studies, electrical and mechanical performance evaluation and related technical documentation.
Key Findings
Regulatory harmonization and stronger lifecycle evidence requirements are supporting sustained demand for outsourced medical device testing and validation
Biological and chemical testing remains a foundational service area for patient-contact implantable and other higher-risk medical devices
Cardiovascular implantables orthopedics diagnostics connected devices and drug delivery systems form the principal high-value downstream demand base
Competition is moving toward integrated laboratory platforms combining testing scientific consulting regulatory support and broader geographic coverage
Market Trends
The Medical Device Testing and Validation Service market is shifting from isolated end-stage compliance testing toward risk-based, lifecycle-oriented evidence generation. Manufacturers increasingly seek testing strategies that begin during material selection and design verification and continue through sterilization, packaging, performance validation, regulatory submission and post-change assessment. This transition is particularly visible in biological safety. ISO 10993-1:2025 reorganized the biological evaluation framework around ISO 14971 risk management and strengthened emphasis on exposure duration, material characterization and biological hazard identification; the FDA subsequently recognized the sixth edition in May 2026. At the same time, electrically powered, software-enabled and connected medical devices are increasing the importance of multidisciplinary validation involving electrical safety, performance, software-related verification, usability, interoperability and cybersecurity-related evidence. Service procurement is therefore moving toward fewer external partners capable of coordinating multiple disciplines and producing documentation suitable for several regulatory markets. Global laboratory networks, standardized quality systems, centralized project management and integrated scientific consulting are becoming more important differentiators than individual test capabilities alone. This favors providers able to combine laboratory capacity with regulatory interpretation and lifecycle program management while maintaining regional facilities close to major MedTech development and manufacturing clusters.
Latest Developments / News
Recent developments show simultaneous tightening of regulatory expectations and consolidation of specialist testing capacity. On January 8, 2026, NAMSA completed the acquisition of selected assets of Labcorp’s Early Development medical device testing business, taking over its U.S. portfolio covering biocompatibility, microbiological and analytical testing and preclinical research; this followed NAMSA’s February 28, 2025 acquisition of WuXi AppTec’s U.S. medical device testing operations. In July 2026, Eurofins agreed to acquire Element Materials Technology’s Life Sciences Testing Services business in North America for an enterprise value of USD 400 million; the business includes 27 laboratories and facilities, and the transaction was expected to close in the fourth quarter of 2026, subject to customary conditions. Regulatory changes have also materially affected testing workflows. The FDA Quality Management System Regulation became effective on February 2, 2026, incorporating ISO 13485:2016 into the U.S. device quality framework and replacing the previous QSIT inspection approach with a new QMSR-aligned process. In Europe, four EUDAMED modules became mandatory on May 28, 2026, including device registration and notified body/certificate modules, increasing the importance of structured, traceable technical evidence. These developments indicate that competition is increasingly centered on integrated capacity, regulatory readiness and the ability to manage complex multi-market testing programs.
Market Dynamics
Drivers
Growth in Medical Device Testing and Validation Service demand is fundamentally linked to increasing device complexity, tighter safety expectations and the need for manufacturers to generate defensible evidence before commercialization. Implantable cardiovascular and orthopedic devices require extensive biological, chemical, mechanical and functional assessment, while diagnostic, patient-monitoring and connected medical devices increasingly combine electronics, sensors, software and communication functions that broaden validation requirements. Regulatory frameworks also require manufacturers to maintain controlled design, risk-management and quality records throughout the product lifecycle. The FDA’s QMSR, effective February 2, 2026, formally aligns U.S. quality-system requirements more closely with ISO 13485:2016 and reinforces risk-based design and development controls. For manufacturers operating across the United States, Europe and Asia, outsourcing specialized testing can reduce the need to maintain every laboratory capability internally and provides access to validated methods, experienced scientists and regulatory documentation systems. These factors support recurring external demand as devices are newly developed, redesigned, transferred between manufacturing sites or adapted for additional markets.
Restraints
The principal constraints arise from testing cost, project duration, laboratory availability and the increasingly specialized nature of study design. Higher-risk products may require sequential biological, chemical, microbiological, packaging, electrical or performance studies, and a failed endpoint or design modification can trigger additional testing and extend product-development schedules. Certain specialist studies require validated equipment, experienced toxicologists, microbiologists or device-specific engineering expertise, limiting interchangeable laboratory capacity. Manufacturers also face differences in regulatory interpretation between jurisdictions despite gradual harmonization, meaning that one evidence package does not always eliminate the need for market-specific technical work. For smaller device developers, the combined cost of preclinical studies, validation, quality documentation and regulatory submissions can materially constrain outsourcing budgets. Service providers must therefore balance rigorous compliance with turnaround time and project economics, while customers increasingly demand early test-strategy optimization to reduce duplicated studies and avoid late-stage redesign.
Opportunities
The strongest incremental opportunities are emerging from higher-complexity devices and from manufacturers seeking integrated testing programs rather than individual laboratory assays. Cardiovascular implants, orthopedic implants, combination-style drug delivery systems and other long-term patient-contact devices create opportunities for broader biological safety, chemical characterization and functional validation programs. Connected patient monitoring and home healthcare devices expand the addressable service scope toward electrical safety, communication performance, software-supported functionality, usability and cybersecurity-related verification. Regulatory alignment can also create opportunities for laboratories capable of designing evidence packages suitable for multiple markets. The new ISO 10993-1:2025 framework places biological evaluation more explicitly within risk management and emphasizes material characterization and biological hazard assessment, increasing the value of early scientific planning rather than relying solely on endpoint testing. Asia-Pacific also offers opportunities as Chinese, Japanese and other regional manufacturers expand international commercialization and require testing documentation acceptable to U.S. and European regulators. Providers with cross-border laboratory networks and common quality systems are positioned to capture this demand.
Challenges
The industry’s longer-term challenge is maintaining scientific consistency while standards, technologies and regulatory expectations continue to evolve. Testing organizations must continually update methods, validation protocols, staff competencies and accreditation scopes, while customers expect previously generated data to remain usable across changing regulatory frameworks. The transition to ISO 10993-1:2025 illustrates this issue: the standard places greater emphasis on integrated risk management, exposure and material characterization, requiring laboratories and manufacturers to reconsider how biological evaluation programs are structured. Consolidation also creates competitive pressure. Larger testing groups can spread expensive laboratory infrastructure across broader customer bases and provide multinational coverage, while specialized regional laboratories compete through technical depth, responsiveness and local regulatory knowledge. At the same time, acquisitions can create customer concerns regarding laboratory concentration, pricing, capacity allocation and continuity of historical study methods. Providers therefore need to combine scale with technical specialization, fast project execution and consistent data quality across multiple facilities.
Value Chain Analysis
The value chain of Medical Device Testing and Validation Service begins with regulatory standards, scientific methods, laboratory infrastructure, reference materials, analytical instruments, environmental chambers, microbiological facilities, electrical safety equipment, mechanical testing systems and specialized scientific talent. These resources support the central service layer, where laboratories and technical organizations translate device characteristics, intended use, patient contact, risk classification and target-market requirements into testing strategies and protocols. Value is created through study design, sample preparation, laboratory execution, method validation, quality assurance, data interpretation and preparation of technical reports that can be incorporated into design history files, biological evaluation documentation, regulatory submissions and quality-system records. The highest-value providers increasingly add regulatory consulting, toxicological assessment, project management and cross-laboratory coordination rather than supplying individual tests in isolation.
Downstream customers include global medical device manufacturers, emerging MedTech developers, diagnostic companies and other device developers requiring independent evidence to support development and commercialization. Procurement decisions are influenced by accreditation, regulatory track record, scientific expertise, available test capacity, turnaround time, geographic proximity and the ability to support several regulatory jurisdictions. Recent consolidation illustrates the strategic importance of laboratory scale: NAMSA’s acquisitions of WuXi AppTec’s U.S. medical device testing operations and selected Labcorp testing assets expanded its available capabilities, while Eurofins’ planned acquisition of Element’s North American Life Sciences Testing Services business highlights continuing investment in laboratory network density and regional coverage.
Segment Insights
Biological and Chemical Testing represents one of the most structurally important segments because biological safety evidence is required across a broad range of patient-contact devices, especially implants and products with prolonged or repeated contact. Testing requirements are increasingly moving beyond simple endpoint biocompatibility assays toward chemical characterization, toxicological evaluation and risk-based biological assessment. The publication of ISO 10993-1:2025 reinforces this direction by linking biological evaluation more closely to ISO 14971 risk management and placing additional emphasis on material characterization, exposure and biological hazards. Microbiology, Sterility and Packaging Validation is another important service category for sterile, single-use and packaged medical devices, where sterilization effectiveness, microbial control, packaging integrity and shelf-life evidence are directly linked to product release and distribution.
Electrical Safety and Performance Testing is particularly important for powered diagnostic systems, patient-monitoring equipment and connected devices, where manufacturers must demonstrate essential performance and safe operation across expected use environments. The Others category captures specialized verification activities that do not fit neatly into the three major laboratory groups but remain part of broader product validation programs. The confirmed report structure therefore reflects a market moving from separate laboratory disciplines toward coordinated testing programs in which biological, microbiological, packaging, electrical and functional evidence are managed as interconnected parts of device development.
Downstream Market Opportunities
Cardiovascular and implantable medical devices represent a particularly attractive demand area because long-term patient contact, high clinical risk and complex materials create extensive requirements for biological safety, chemical characterization, mechanical performance and preclinical validation. Orthopedic and surgical devices similarly generate recurring testing demand associated with implants, surgical instruments, sterile packaging and manufacturing changes. Diagnostic and in vitro diagnostic devices create a different testing profile emphasizing analytical performance, electrical safety, sample interaction and system reliability, while patient monitoring and connected medical devices are becoming more technically complex as sensors, wireless communication and software functionality become more deeply integrated. Drug delivery and home healthcare devices also create opportunities as care increasingly extends beyond hospitals and devices must operate reliably in less controlled user environments.
For testing organizations, the commercial opportunity increasingly lies in supporting complete development programs rather than isolated test orders. Manufacturers that intend to commercialize the same device across North America, Europe and Asia require early coordination of testing plans so that biological, packaging, electrical and performance evidence can support multiple submissions with minimal duplication. Providers capable of combining laboratory testing, scientific assessment, regulatory interpretation and project management are therefore likely to capture a larger share of customer spending. The confirmed downstream structure encompasses cardiovascular and implantable, orthopedic and surgical, diagnostic and IVD, connected monitoring, drug delivery and home healthcare applications.
Regional Insights
North America remains a core market for medical device testing and validation because of its large MedTech development base, substantial number of innovative device companies and detailed FDA regulatory requirements. The February 2026 implementation of QMSR has further aligned U.S. quality-system requirements with ISO 13485:2016 while introducing a new FDA inspection framework, reinforcing the importance of risk management, design controls and well-structured validation documentation. Recent acquisitions involving NAMSA, WuXi AppTec’s U.S. testing operations and Labcorp’s Early Development medical device testing business also demonstrate the strategic value placed on North American laboratory capacity.
Europe is another major demand center, supported by MDR and IVDR compliance requirements, extensive notified-body involvement and a mature TIC and specialist laboratory ecosystem. The mandatory use of four EUDAMED modules from May 28, 2026 further strengthens requirements for structured device, certificate and market-surveillance information. Asia-Pacific is increasingly important both as a medical device manufacturing base and as a source of internationally expanding MedTech companies. China has developed a broad domestic testing infrastructure and growing cross-border regulatory demand, while Japan maintains stringent product safety, quality and certification requirements. Consequently, multinational providers increasingly combine global quality systems with regional laboratories, while local Asian providers compete through proximity, cost efficiency and familiarity with domestic regulatory pathways.
Competitive Landscape Analysis
The competitive landscape is characterized by a combination of diversified global testing, inspection and certification groups; specialized MedTech laboratories and development service providers; and strong regional laboratories. The confirmed participant base includes SGS, TÜV SÜD AG, Intertek Group plc, Eurofins Scientific SE, North American Science Associates, LLC (NAMSA), Element Materials Technology, TÜV Rheinland, UL Solutions Inc., Bureau Veritas SA, DEKRA SE, WuXi AppTec Co., Ltd., Quest Global Services Pte. Ltd., Centre Testing International, Pony Testing International Group Co., Ltd., SUDATEST and Japan Quality Assurance Organization. Global TIC organizations compete through broad accreditation portfolios, international laboratory networks and established relationships with multinational manufacturers, while specialist medical device laboratories compete through biological safety expertise, device-specific scientific capabilities, preclinical services and regulatory familiarity. Chinese and Japanese providers strengthen the market’s regional layer by supporting domestic manufacturers and locally required testing.
Competition is increasingly shifting from individual test pricing toward breadth of capabilities, regulatory integration, turnaround time, multi-site consistency and the ability to support a product across several stages of development. NAMSA’s 2025 acquisition of WuXi AppTec’s U.S. medical device testing operations and its January 2026 acquisition of selected Labcorp testing assets illustrate consolidation around specialized MedTech capabilities. Eurofins’ July 2026 agreement to acquire Element’s North American Life Sciences Testing Services business similarly points toward further network consolidation if the transaction closes as planned. Future competition is therefore likely to focus on integrated testing portfolios, scientific depth, regulatory credibility, laboratory capacity, cross-border project coordination and the ability to convert testing results into regulator-ready evidence efficiently.
Report Scope
This report is a detailed and comprehensive analysis for global Medical Device Testing and Validation Service market. Both quantitative and qualitative analyses are presented by company, by region & country, by Testing and Validation Scope Types and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Medical Device Testing and Validation Service market size and forecasts, in consumption value ($ Million), 2021-2032
Global Medical Device Testing and Validation Service market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Medical Device Testing and Validation Service market size and forecasts, by Testing and Validation Scope Types and by Application, in consumption value ($ Million), 2021-2032
Global Medical Device Testing and Validation Service market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Medical Device Testing and Validation Service
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Medical Device Testing and Validation Service market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include SGS, TÜV SÜD AG, Intertek Group plc, Eurofins Scientific SE, North American Science Associates, LLC (NAMSA), Element Materials Technology, TÜV Rheinland, UL Solutions Inc., Bureau Veritas SA, DEKRA SE, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Medical Device Testing and Validation Service market is split by Testing and Validation Scope Types and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Testing and Validation Scope Types and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Market segment by Testing and Validation Scope Types
Biological and Chemical Testing
Microbiology, Sterility and Packaging Validation
Electrical Safety and Performance Testing
Others
Market segment by Medical Device Risk Class Types
Class I Devices (Low Risk)
Class II Devices (Moderate Risk)
Class III Devices (High Risk)
Market segment by Product Lifecycle Stage Types
Preclinical and Design Verification Testing
Clinical Validation Testing
Commercial Release and Post-Market Validation
Market segment by Application
Cardiovascular and Implantable Medical Devices
Orthopedic and Surgical Medical Devices
Diagnostic and In Vitro Diagnostic Devices
Patient Monitoring and Connected Medical Devices
Drug Delivery and Home Healthcare Devices
Others
Market segment by players, this report covers
SGS
TÜV SÜD AG
Intertek Group plc
Eurofins Scientific SE
North American Science Associates, LLC (NAMSA)
Element Materials Technology
TÜV Rheinland
UL Solutions Inc.
Bureau Veritas SA
DEKRA SE
WuXi AppTec Co., Ltd.
Quest Global Services Pte. Ltd.
Centre Testing International
Pony Testing International Group Co., Ltd.
SUDATEST
Japan Quality Assurance Organization (JQA)
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Medical Device Testing and Validation Service product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Medical Device Testing and Validation Service, with revenue, gross margin, and global market share of Medical Device Testing and Validation Service from 2021 to 2026.
Chapter 3, the Medical Device Testing and Validation Service competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Testing and Validation Scope Types and by Application, with consumption value and growth rate by Testing and Validation Scope Types, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Medical Device Testing and Validation Service market forecast, by regions, by Testing and Validation Scope Types and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Medical Device Testing and Validation Service.
Chapter 13, to describe Medical Device Testing and Validation Service research findings and conclusion.
Summary:
Get latest Market Research Reports on Medical Device Testing and Validation Service. Industry analysis & Market Report on Medical Device Testing and Validation Service is a syndicated market report, published as Global Medical Device Testing and Validation Service Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Medical Device Testing and Validation Service market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.